Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 12, 2010, Pages 3565-3568

  Cho, Tang Peng ^a   Long, Yang Fang ^a   Gang, Lin Zhi ^a   Yang, Wang ^a   Jun, Lu He ^a   Yuan, Shen Guang ^a   Hong, Fu Jian ^a   Lin, Wang ^a   Liang, Guan Dong ^a   Lei, Zhang ^a   Jing, Luo Jing ^a   Shen, Gong Ai ^a   Hong, She Gao ^a   Dan, Wang ^a   Ying, Feng ^b   Ke, Yan Pang ^a,b   Ying, Leng ^b   Jun, Feng ^a   Tai, Mong Xian ^a  

^a Shanghai Hengrui Pharmaceuticals Co Ltd   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Azobicyclo 3.3.0 octane derivatives; Dipeptidyl peptidase 4; Oral glucose tolerance test; Type 2 diabetes mellitus

Indexed keywords

AZOBICYCLO[3.3.0]OCTANE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE TOLERANCE TEST; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

ANIMALS; ANTIGENS, CD26; AZO COMPOUNDS; BICYCLO COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED ICR; OCTANES; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954214690     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.120     Document Type: Article

References (26)

1. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R.S. Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Webe J. Med. Chem. 48 2005 141
2. J.H. Shubrook, R.A. Colucci, and F.L. Schwartz Formulary 43 2008 122
3. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, K. Prasad, B.L. Mangold, M.E. Russell, and T.E. Hughes J. Med. Chem. 46 2003 2774
4. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, L.M. Simpkins, P.C. Taunk, Q. Huang, S.P. Han, B. Abboa-Offei, A. Wang, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y.J. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, and L.G. Hamann J. Med. Chem. 48 2005 5025
5. J.U. Peters Curr. Top. Med. Chem. 7 2007 579
6. J. Feng, A.Y. Zhang, M.B. Wallace, J.A. Stafford, S.W. Kaldor, D.B. Kassel, M. Navre, L.H. Shi, R.J. Skene, T. Asakawa, K. Takeuchi, R.D. Xu, D.R. Webb, and S.L. Gwaltney J. Med. Chem. 51 2008 4357
7. R. Gupta, S.S. Walunj, R.K. Tokala, K.V.L. Parsa, S.K. Singh, and M. Pal Curr. Drug Targets 10 2009 71
8. J.F. Gautier, S. Fetita, and E. Sobngwi Diabetes Metab. 31 2005 233
9. M.A. Nauck, D. Wollschlager, J. Werner, J.J. Holst, C. Orskov, W. Creutzfeldt, and B. Willams Diabetologia 39 1996 1546
10. M.A. Nauck Acta Diabetol. 35 1998 117
11. J.F. Gautier, S. Fetita, E. Sobngwi, and C. Salaün-Martin Diabetes Metab. 31 2005 233
12. S.A. Miller, E.L. St. Onge, and J.R. Taylor Formulary 43 2008 122
13. J.F. Gautier, S.P. Choukem, and J. Girard Diabetes Metab. 34 2008 S65
14. E. Sebokova, A.D. Christ, M. Boehringer, and J. Mizrahi Curr. Top. Med. Chem. 7 2007 547
15. S.H. Havale, and M. Pal Bioorg. Med. Chem. 17 2009 1783
16. P.C. Tang, F.L. Yang, Z.G. Lin, Y. Wang, Q. Wang, Y.L. Li, L. Zhang, Y. Leng, Feng Y., A.S. Gong, and Feng J. Bioorg. Med. Chem. Lett. 20 2010 3521
17. M.D. Mihovilovic, C. Adelwöhrer, and P. Stanetty ARKIVOC 2 2001 28
18. D.P. Becker, and D.L. Flynn Tetrahedron 49 1993 5047
19. +.
20. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.E. Dunning, B.L. Mangold, M.D. Mone, M.E. Russell, S.C. Weldon, and T.E. Hughes J. Med. Chem. 45 2002 2362
21. P.C. Tang, Z.G. Lin, Y. Wang, F.L. Yang, Q. Wang, J.H. Fu, L. Zhang, A.S. Gong, J.J. Luo, J. Dai, G.H. She, D.D. Si, and J. Feng Chin. Chem. Lett. 21 2010 253
22. Y. Kitano, K. Chiba, and M. Tada Synlett 1999 288
23. 50 values for DPP-4, DPP-8, and DPP-9 were obtained by chemical Luminescent assay using Glo™ Protease Assay Kit (cat. G 8350). For assay conditions, see: Tang, P. C.; Lin, Z. G.; Lu, H. J.; Zhao, F. Q.; Li, L.; Yang, F. L.; Fu, J. H.; Wang, L.; Shen, G. Y.; Guan, D. L. WO2009094866.
24. G.R. Lankas, B. Leiting, R. Sinha Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.-C. Chan, S. Edmondson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, K.A. Lyons, H.O. Ok, R.A. Patel, A.N. Petrov, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry Diabetes 54 2005 2988
25. 1/2 for 2j, >50 d. The stability of the inhibitors in buffered, aqueous solution (pH 7.2) was monitored by reverse-phase HPLC. The inhibitors with half-lives of less than 48 h decompose to multiple products which have not been characterized E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, K. Prasad, B.L. Mangold, M.E. Russell, and T.E. Hughes J. Med. Chem. 46 2003 2774
26. D.M. Ashworth, B. Atrash, G.R. Baker, A.J. Baxter, P.D. Jenkins, D.M. Jones, and M. Szelke Bioorg. Med. Chem. Lett. 6 1996 2745